{ "api_version": "1", "request": { "url": "https://clinicaltrialsfind.com/api/v1/search.json?condition=ER+Positive&page=10", "query": { "condition": "ER Positive", "page": 10 }, "page_size": 10 }, "pagination": { "page": 10, "page_size": 10, "total_count": 418, "total_pages": 42, "next_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?condition=ER+Positive&page=11&page_size=10", "previous_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?condition=ER+Positive&page=9&page_size=10" }, "source": "remote", "last_synced_at": "2026-11-13T17:24:06.083Z", "attribution": "Data derived from public ClinicalTrials.gov records. The official record at https://clinicaltrials.gov/ remains the source of truth for current availability, contacts, and full study details.", "notes": [ "This endpoint exposes only public summary fields — no participant contact emails, phone numbers, or scraped investigator contact details.", "For contact information and full protocol detail, follow each trial's `official_url` to the ClinicalTrials.gov record.", "This API is a navigational aid. It does not provide medical advice, eligibility determinations, or compensation guarantees." ], "trials": [ { "nct_id": "NCT02291913", "title": "Everolimus Combined With Anti-estrogen Therapy in Hormone-Receptor-Positive HER-2 Negative Advanced Breast Cancer", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Breast Cancer" ], "interventions": [ { "name": "Everolimus", "type": "DRUG" }, { "name": "Exemestane", "type": "DRUG" }, { "name": "Tamoxifen", "type": "DRUG" }, { "name": "Fulvestrant", "type": "DRUG" }, { "name": "Anastrozole", "type": "DRUG" }, { "name": "Letrozole", "type": "DRUG" }, { "name": "Toremifine", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "SCRI Development Innovations, LLC", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "FEMALE", "summary": "18 Years and older · Female only" }, "enrollment_count": 48, "start_date": "2014-12-18", "completion_date": "2019-01-31", "has_results": true, "last_update_posted_date": "2020-02-17", "last_synced_at": "2026-11-13T17:24:06.083Z", "location_count": 8, "location_summary": "Fort Myers, Florida • Hollywood, Florida • Pensacola, Florida + 5 more", "locations": [ { "city": "Fort Myers", "state": "Florida" }, { "city": "Hollywood", "state": "Florida" }, { "city": "Pensacola", "state": "Florida" }, { "city": "West Palm Beach", "state": "Florida" }, { "city": "Terre Haute", "state": "Indiana" } ], "official_url": "https://clinicaltrials.gov/study/NCT02291913" }, { "nct_id": "NCT07191717", "title": "Imlunestrant and Abemaciclib for the Treatment of Estrogen Receptor Positive Breast Cancer in Patients With Minimal Residual Disease, MIRI Trial", "overall_status": "RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Anatomic Stage I Breast Cancer AJCC v8", "Anatomic Stage II Breast Cancer AJCC v8", "Anatomic Stage III Breast Cancer AJCC v8", "Invasive Breast Carcinoma", "Localized Estrogen Receptor-Positive Breast Carcinoma", "Localized Human Epidermal Growth Factor Receptor (HER2)-Negative Breast Carcinoma" ], "interventions": [ { "name": "Abemaciclib", "type": "DRUG" }, { "name": "Biospecimen Collection", "type": "PROCEDURE" }, { "name": "Imlunestrant", "type": "DRUG" }, { "name": "Questionnaire Administration", "type": "OTHER" }, { "name": "Radiologic Imaging Procedure", "type": "PROCEDURE" } ], "intervention_types": [ "DRUG", "PROCEDURE", "OTHER" ], "sponsor": "Jonsson Comprehensive Cancer Center", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 42, "start_date": "2026-05-18", "completion_date": "2031-04-30", "has_results": false, "last_update_posted_date": "2026-08-20", "last_synced_at": "2026-11-13T17:24:06.083Z", "location_count": 1, "location_summary": "Los Angeles, California", "locations": [ { "city": "Los Angeles", "state": "California" } ], "official_url": "https://clinicaltrials.gov/study/NCT07191717" }, { "nct_id": "NCT01698918", "title": "Open-label, Phase II, Study of Everolimus Plus Letrozole in Postmenopausal Women With ER+, HER2- Metastatic or Locally Advanced Breast Cancer", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Hormone Receptor Positive Breast Cancer" ], "interventions": [ { "name": "Everolimus", "type": "DRUG" }, { "name": "Letrozole", "type": "DRUG" }, { "name": "Exemestane", "type": "DRUG" }, { "name": "Alcohol-free dexamethasone mouth rinse (Stomatitis sub-study)", "type": "DRUG" }, { "name": "Standard of care to treat stomatitis (Stomatitis sub-study)", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Novartis Pharmaceuticals", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "FEMALE", "summary": "18 Years and older · Female only" }, "enrollment_count": 202, "start_date": "2013-03-07", "completion_date": "2021-01-13", "has_results": true, "last_update_posted_date": "2023-05-03", "last_synced_at": "2026-11-13T17:24:06.083Z", "location_count": 15, "location_summary": "Birmingham, Alabama • Gilbert, Arizona • Loma Linda, California + 12 more", "locations": [ { "city": "Birmingham", "state": "Alabama" }, { "city": "Gilbert", "state": "Arizona" }, { "city": "Loma Linda", "state": "California" }, { "city": "Long Beach", "state": "California" }, { "city": "Park Ridge", "state": "Illinois" } ], "official_url": "https://clinicaltrials.gov/study/NCT01698918" }, { "nct_id": "NCT05187832", "title": "A Study of AND019 in Women With ER Positive HER2 Negative Advanced or Metastatic Breast Cancer", "overall_status": "RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Advanced or Metastatic Breast Cancer" ], "interventions": [ { "name": "AND019 PO QD", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Kind Pharmaceuticals LLC", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "FEMALE", "summary": "18 Years and older · Female only" }, "enrollment_count": 61, "start_date": "2022-10-05", "completion_date": "2026-11", "has_results": false, "last_update_posted_date": "2026-02-27", "last_synced_at": "2026-11-13T17:24:06.083Z", "location_count": 1, "location_summary": "Nashville, Tennessee", "locations": [ { "city": "Nashville", "state": "Tennessee" } ], "official_url": "https://clinicaltrials.gov/study/NCT05187832" }, { "nct_id": "NCT01439711", "title": "Letrozole in Treating Postmenopausal Women With Ductal Carcinoma in Situ", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Breast Cancer" ], "interventions": [ { "name": "letrozole", "type": "DRUG" }, { "name": "MRI", "type": "PROCEDURE" }, { "name": "conventional surgery", "type": "PROCEDURE" } ], "intervention_types": [ "DRUG", "PROCEDURE" ], "sponsor": "Alliance for Clinical Trials in Oncology", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "FEMALE", "summary": "18 Years and older · Female only" }, "enrollment_count": 108, "start_date": "2012-02", "completion_date": "2018-01", "has_results": true, "last_update_posted_date": "2018-03-27", "last_synced_at": "2026-11-13T17:24:06.083Z", "location_count": 32, "location_summary": "Los Angeles, California • Oakland, California • San Francisco, California + 22 more", "locations": [ { "city": "Los Angeles", "state": "California" }, { "city": "Oakland", "state": "California" }, { "city": "San Francisco", "state": "California" }, { "city": "Denver", "state": "Colorado" }, { "city": "Newark", "state": "Delaware" } ], "official_url": "https://clinicaltrials.gov/study/NCT01439711" }, { "nct_id": "NCT00371345", "title": "Study of Dasatinib (BMS-354825) in Patients With Advanced Estrogen/Progesterone Receptor-positive (ER+/PR+) or Her2/Neu-positive (Her2/Neu+)Breast Cancer", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Breast Cancer", "Metastasis" ], "interventions": [ { "name": "Dasatinib", "type": "DRUG" }, { "name": "Dasatinib 100 mg", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Bristol-Myers Squibb", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "FEMALE", "summary": "18 Years and older · Female only" }, "enrollment_count": 92, "start_date": "2006-12", "completion_date": "2009-05", "has_results": true, "last_update_posted_date": "2011-04-26", "last_synced_at": "2026-11-13T17:24:06.083Z", "location_count": 7, "location_summary": "San Francisco, California • Jacksonville, Florida • Boston, Massachusetts + 4 more", "locations": [ { "city": "San Francisco", "state": "California" }, { "city": "Jacksonville", "state": "Florida" }, { "city": "Boston", "state": "Massachusetts" }, { "city": "The Bronx", "state": "New York" }, { "city": "Chapel Hill", "state": "North Carolina" } ], "official_url": "https://clinicaltrials.gov/study/NCT00371345" }, { "nct_id": "NCT03128619", "title": "Copanlisib, Letrozole, and Palbociclib in Treating Patients With Hormone Receptor Positive HER2 Negative Stage I-IV Breast Cancer", "overall_status": "TERMINATED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Estrogen Receptor Positive", "HER2/Neu Negative", "Invasive Breast Carcinoma", "Multifocal Breast Carcinoma", "Postmenopausal", "Progesterone Receptor Positive", "Stage I Breast Cancer", "Stage IA Breast Cancer", "Stage IB Breast Cancer", "Stage II Breast Cancer", "Stage IIA Breast Cancer", "Stage IIB Breast Cancer", "Stage III Breast Cancer", "Stage IIIA Breast Cancer", "Stage IIIB Breast Cancer", "Stage IIIC Breast Cancer", "Stage IV Breast Cancer" ], "interventions": [ { "name": "Biopsy of Breast", "type": "PROCEDURE" }, { "name": "Copanlisib", "type": "DRUG" }, { "name": "Laboratory Biomarker Analysis", "type": "OTHER" }, { "name": "Letrozole", "type": "DRUG" }, { "name": "Palbociclib", "type": "DRUG" }, { "name": "Pharmacological Study", "type": "OTHER" } ], "intervention_types": [ "PROCEDURE", "DRUG", "OTHER" ], "sponsor": "Jonsson Comprehensive Cancer Center", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "19 Years", "maximum_age": null, "sex": "ALL", "summary": "19 Years and older" }, "enrollment_count": 10, "start_date": "2017-08-02", "completion_date": "2022-03-31", "has_results": false, "last_update_posted_date": "2022-09-26", "last_synced_at": "2026-11-13T17:24:06.083Z", "location_count": 1, "location_summary": "Los Angeles, California", "locations": [ { "city": "Los Angeles", "state": "California" } ], "official_url": "https://clinicaltrials.gov/study/NCT03128619" }, { "nct_id": "NCT04305236", "title": "Neo-Adjuvant Abemaciclib With Fulvestrant in Patients With ER/PR +HER Negative Breast Cancer", "overall_status": "TERMINATED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Breast Neoplasm", "Hormone Receptor Positive Breast Carcinoma" ], "interventions": [ { "name": "Abemaciclib", "type": "DRUG" }, { "name": "Fulvestrant", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "University of California, Irvine", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "FEMALE", "summary": "18 Years and older · Female only" }, "enrollment_count": 1, "start_date": "2020-07-23", "completion_date": "2022-02-16", "has_results": true, "last_update_posted_date": "2023-06-06", "last_synced_at": "2026-11-13T17:24:06.083Z", "location_count": 1, "location_summary": "Orange, California", "locations": [ { "city": "Orange", "state": "California" } ], "official_url": "https://clinicaltrials.gov/study/NCT04305236" }, { "nct_id": "NCT02316509", "title": "A Study of GDC-0927 in Postmenopausal Women With Locally Advanced or Metastatic Estrogen Receptor Positive Breast Cancer", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Breast Cancer" ], "interventions": [ { "name": "GDC-0927", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Genentech, Inc.", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "FEMALE", "summary": "18 Years and older · Female only" }, "enrollment_count": 43, "start_date": "2015-03-17", "completion_date": "2020-01-10", "has_results": false, "last_update_posted_date": "2020-10-05", "last_synced_at": "2026-11-13T17:24:06.083Z", "location_count": 5, "location_summary": "Boston, Massachusetts • New York, New York • Germantown, Tennessee + 1 more", "locations": [ { "city": "Boston", "state": "Massachusetts" }, { "city": "Boston", "state": "Massachusetts" }, { "city": "New York", "state": "New York" }, { "city": "Germantown", "state": "Tennessee" }, { "city": "Nashville", "state": "Tennessee" } ], "official_url": "https://clinicaltrials.gov/study/NCT02316509" }, { "nct_id": "NCT01004744", "title": "Pre-Surgical Intervention for Targeted Therapies for Breast Cancer", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "NA" ], "conditions": [ "Invasive Breast Cancer" ], "interventions": [ { "name": "Anastrozole", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Columbia University", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "21 Years", "maximum_age": null, "sex": "FEMALE", "summary": "21 Years and older · Female only" }, "enrollment_count": 10, "start_date": "2007-07", "completion_date": "2009-08", "has_results": true, "last_update_posted_date": "2021-01-11", "last_synced_at": "2026-11-13T17:24:06.083Z", "location_count": 1, "location_summary": "New York, New York", "locations": [ { "city": "New York", "state": "New York" } ], "official_url": "https://clinicaltrials.gov/study/NCT01004744" } ] }